USE OF INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN 7 AND TISSUE INHIBITOR OF METALLOPROTEINASE 2 IN THE MANAGEMENT OF RENAL REPLACEMENT THERAPY
The present invention provides methods and compositions for managing renal replacement therapy. A risk score, which is determined from a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and/or a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2),...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English French German |
Published |
06.01.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!